An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essent

Status:
Terminated

Trial end date:
2006-09-30

Target enrollment:

Participant gender:

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

Phase 3

Merck Sharp & Dohme Corp.

Hydrochlorothiazide
Losartan